We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PL:NYSEPlanet Labs PBC Analysis

Data as of 2026-09-04 - not real-time

$18.35

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Planet Labs PBC trades at $18.35, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Across the trailing 30 sessions it lost 17.9%. Momentum indicators put RSI at 29.3 (oversold) with MACD reading bearish. Price has been bracketed by support at $17.83 and resistance at $25.53.
The shares look overvalued, trading on 1835.0 times earnings above a sector average of 28.3. The average analyst target implies 111.0% above today's level. Revenue is growing at 42.1% on a -111.2% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 60.5%, a beta of 2.49 and a maximum drawdown of 64.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
All three time horizons resolve to sell, carrying 4/10 conviction.

Top Market Events

Both companies are unprofitable but growing rapidly, though one carries significantly lower valuation multiples and...Planet Labs PL stock wins 7-figure European defense contract.One trades at 21.9x forward earnings with $8.6B in free cash flow; the other with persistent losses and satellite risk.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • RSI at 29.3 signals oversold conditions
  • Trading below the 200-day average of 26.94

Medium Term

1–3 years
Cautious
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • RSI at 29.3 signals oversold conditions
  • P/E of 1835.0 versus sector average of 28.3

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • P/E of 1835.0 versus sector average of 28.3
  • Negative profit margin of -111.2%
  • Analyst targets imply +111.0% versus the current price

Key Metrics & Analysis

Financial Health

Revenue Growth42.10%
Profit Margin-111.17%
P/E Ratio1835.0
ROE-83.98%
ROA-5.87%
Debt/Equity109.99
P/B Ratio14.7
Op. Cash Flow$132.5M
Free Cash Flow$84.9M
Industry P/E28.3

Technical Analysis

TrendBearish
RSI29.3
Support$17.83
Resistance$25.53
MA 20$22.12
MA 50$23.73
MA 200$26.94
MACDBearish
VolumeIncreasing
Fear & Greed Index96.14

Valuation

Fair Value$8.87
Target Price$38.73
Upside/Downside111.05%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.49
Volatility60.47%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.